Navigation Links
Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP

VIENNA, Austria, June 11, 2007 /PRNewswire/ -- GlaxoSmithKline plc announced results from an international, pivotal Phase III study of its investigational non-peptide oral platelet growth factor, PROMACTA(R) (eltrombopag olamine). Data from this study showed that PROMACTA at 50-75mg once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in adult patients with chronic idiopathic thrombocytopenic purpura (ITP). These patients had previously received and failed current standard ITP treatments. These data, which are part of a six-week study of PROMACTA in patients with chronic ITP, were presented at the 12th congress of the European Hematology Association (EHA) in Vienna, Austria.(1)

"ITP is a condition that can be serious for some individuals, or those who fail to respond to therapy and not only puts patients at risk of bleeding, but may also cause severe fatigue, bruises and complications during surgery or pregnancy," says Drew Provan, M.D., Senior Lecturer in Hematology, Department of Hematology, Royal London Hospital, U.K. and investigator for this trial. "Options are particularly limited for those patients who fail to respond to primary treatment altogether and those who initially respond and then fail. These trial results demonstrate that PROMACTA may represent the potential for a new oral therapy to reduce the number of bleeding episodes in ITP patients."

There are estimated to be between 50,000-100,000 individuals diagnosed with chronic ITP in the U.S. In Europe, primary ITP is estimated to affect 50 to 100 new persons per million per year.(2) People with ITP often bleed from small blood vessels causing bruises, nosebleeds, bleeding from the gums during dental work or other bleeding that is difficult to stop. The predicted five- year mortality rates for ITP patients with persistent low platelet counts range from 2.2% for patients younger than 4
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
11. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
Post Your Comments:
(Date:10/31/2014)... YORK , Oct. 31, 2014 Though ... cell technologies are expected to show an annual increase ... market value of nearly $1 billion, according to Kalorama ... revenues from proprietary stem cell therapeutics that have gained ... authorities. "As drug developers tackle ever more ...
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... Oct. 30, 2014   ViaDerma, Inc. ... bringing new products to market, has recently released ... TetraStem is a topical liquid tetracycline-based antibiotic that ... can convert oral medication active ingredients into topical ... first aid antibiotic to help prevent skin infection ...
Breaking Medicine Technology:Report: Stem Cell Technologies Market Growing 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... Henry Schein, Inc. (NASDAQ: HSIC ), ... office-based practitioners, announced today that Ferdinand Jahnel, Vice ... King 9th Annual Best Ideas Conference 2011. The conference is ... City. Henry Schein,s presentation is scheduled to ...
... 2011 PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... and chief executive officer, will present at the following upcoming ... UBS Global Life Sciences Conference Tuesday, September 20, 2011 ... JMP Securities Healthcare Conference Tuesday, September 27, 2011 2:30 ...
Cached Medicine Technology:Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011 2
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... Americans say that either they or a family member ... the latest issue of The Gerontological Society of America,s ... ), which goes on to show that Americans strongly ... patients, end-of-life health care wishes. , This PP&AR ... ," features 12 articles that present new ways of ...
(Date:10/31/2014)... 2014 North Shore Eye Care today ... Long Island and the addition of leading ophthalmologist, William ... to North Shore Eye Care Medical Director, Jeffrey Martin, ... of the Department of Ophthalmology of Winthrop-University Hospital and ... City for more than 30 years. He has been ...
(Date:10/31/2014)... York, NY (PRWEB) October 31, 2014 ... of the most remarkable gifts of life — building ... for matching extraordinary surrogate mothers and donors with hopeful ... individuals in unforeseen circumstances. , It’s a collective aptitude ... surrogacy agencies, surrogacy lawyers, and fertility clinics that help ...
(Date:10/31/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... U.S. indoor air quality (IAQ) market is expected to grow ... rate (CAGR) of 7% over the next five years. The ... of 7.4%. , Since 2012, continuing media attention focused ... infectious diseases such as bird flu and the increase in ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... INCREASE 23 PERCENTSAN DIEGO, Feb. 17 Volcano Corporation ... development, manufacturing and sales of products for the diagnosis ... reported that revenues for the full year 2008 increased ... for the fourth quarter of 2008 increased 23 percent ...
... and those also taking steroids are most vulnerable, study ... class of medications used widely to treat rheumatoid arthritis ... shingles, especially among older people and those who are ... appearing in the Feb. 18 issue of the ...
... Foresight Credited with Industry,s Strong Business Performance in Tough ... economy in crisis, it,s clear that strong domestic industries ... Food and Drug Administration (FDA) mandated trans fat appear ... products to reduce or eliminate trans fat content. ...
... and partners,of Greenway Medical Technologies, led by the ... Barnes, recently returned from,Washington, D.C. where they played ... healthcare information technology (HIT) portion of,the $787 billion ... law. , Greenway,s leadership ...
... alleviate the stress of trying to figure out the ,Nanny ... - there are two things parents never imagined ... of America,s most exciting female political figures having issues due ... an issue. That,s why Sittercity.com, America,s largest and most ...
... Feb. 17 National Pharmaceutical Council President Dan ... economic stimulus package, which includes $1.1 billion for ... package into law, President Obama has made a ... for comparative effectiveness research also is a major ...
Cached Medicine News:Health News:Volcano Reports Full Year Revenues Increase 31 Percent 2Health News:Volcano Reports Full Year Revenues Increase 31 Percent 3Health News:Volcano Reports Full Year Revenues Increase 31 Percent 4Health News:Volcano Reports Full Year Revenues Increase 31 Percent 5Health News:Volcano Reports Full Year Revenues Increase 31 Percent 6Health News:Volcano Reports Full Year Revenues Increase 31 Percent 7Health News:Volcano Reports Full Year Revenues Increase 31 Percent 8Health News:Volcano Reports Full Year Revenues Increase 31 Percent 9Health News:Volcano Reports Full Year Revenues Increase 31 Percent 10Health News:Volcano Reports Full Year Revenues Increase 31 Percent 11Health News:Volcano Reports Full Year Revenues Increase 31 Percent 12Health News:Volcano Reports Full Year Revenues Increase 31 Percent 13Health News:Volcano Reports Full Year Revenues Increase 31 Percent 14Health News:Rheumatoid Arthritis Drugs Raise Shingles Risk 2Health News:Rheumatoid Arthritis Drugs Raise Shingles Risk 3Health News:Farmers' Trans Fat Solution Efforts Preserve $700 Million Market 2Health News:Farmers' Trans Fat Solution Efforts Preserve $700 Million Market 3Health News:Greenway Medical Technologies Assists Capitol Hill With Shaping of The President's Stimulus Package 2Health News:Greenway Medical Technologies Assists Capitol Hill With Shaping of The President's Stimulus Package 3Health News:Sittercity.com Makes Nanny Taxes Less Taxing 2Health News:Sittercity.com Makes Nanny Taxes Less Taxing 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: